{"url":"https://lda.gov/api/v1/filings/4bb7871f-5120-4277-b7b6-165eea06b7d7/","filing_uuid":"4bb7871f-5120-4277-b7b6-165eea06b7d7","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2025,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/4bb7871f-5120-4277-b7b6-165eea06b7d7/print/","filing_document_content_type":"text/html","income":null,"expenses":"1180000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Adam Brand, Vice President, Government Affairs","dt_posted":"2025-04-17T17:32:29-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2440 Research Drive","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Rockville","registrant_state":"MD","registrant_zip":"20850","registrant":{"id":401093052,"url":"https://lda.gov/api/v1/registrants/401093052/","house_registrant_id":null,"name":"OTSUKA AMERICA PHARMACEUTICAL, INC.","description":"Pharmaceutical research and development","address_1":"2440 Research Drive","address_2":null,"address_3":null,"address_4":null,"city":"Rockville","state":"MD","state_display":"Maryland","zip":"20850","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMELIA SUERMANN","contact_telephone":"+1 202-997-6592","dt_updated":"2026-07-28T09:37:13.144927-04:00"},"client":{"id":197760,"url":"https://lda.gov/api/v1/clients/197760/","client_id":12,"name":"OTSUKA AMERICA PHARMACEUTICAL, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-04-20"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues relating to agitation in Alzheimer's disease, early detection of PTSD, mental health parity and coordinated care, mental health equity, PBM reform, issues related to rare nephrology, 340B reform, psychedelics treatments for PTSD and mental health, BIOSECURE Act, and the Ensuring Pathways to Innovative Cures (EPIC) Act (S.832/HR 1492).","foreign_entity_issues":"Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.","lobbyists":[{"lobbyist":{"id":144439,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"DWIGHT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147686,"prefix":null,"prefix_display":null,"first_name":"AMELIA","nickname":null,"middle_name":null,"last_name":"SUERMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Provisions related to the Continuing Appropriations and Other Matters Act, 2025; and issues related to budget reconciliation.","foreign_entity_issues":"Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.","lobbyists":[{"lobbyist":{"id":144439,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"DWIGHT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147686,"prefix":null,"prefix_display":null,"first_name":"AMELIA","nickname":null,"middle_name":null,"last_name":"SUERMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to tax reform efforts, issues stemming from the Tax Cuts and Jobs Act of 2017, and other corporate tax issues.","foreign_entity_issues":"Otsuka (Japan), identified on filers Registration Statement (LD-1), as its parent organization has an interest in the listed issues.","lobbyists":[{"lobbyist":{"id":144439,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"DWIGHT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147686,"prefix":null,"prefix_display":null,"first_name":"AMELIA","nickname":null,"middle_name":null,"last_name":"SUERMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"VET","general_issue_code_display":"Veterans","description":"Veterans Affairs, Mental Health, and post-traumatic stress disorder (PTSD). Specifically, health care policies relating to mental health and PTSD. Veterans Affairs authorizations and appropriations issues related to mental health and PTSD.","foreign_entity_issues":"Otsuka (Japan), identified on filers Registration Statement (LD-1), as its parent organization has an interest in the listed issues.","lobbyists":[{"lobbyist":{"id":144439,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"DWIGHT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147686,"prefix":null,"prefix_display":null,"first_name":"AMELIA","nickname":null,"middle_name":null,"last_name":"SUERMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Implementation of the Inflation Reduction Act. Issues related to Medicare Part D redesign's impact on low-income subsidy beneficiaries.","foreign_entity_issues":"Otsuka (Japan), identified on filer's Registration Statement (LD-1), as its parent organization has an interest in the listed issues.","lobbyists":[{"lobbyist":{"id":144439,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"DWIGHT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147686,"prefix":null,"prefix_display":null,"first_name":"AMELIA","nickname":null,"middle_name":null,"last_name":"SUERMANN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}